Expression of the transcription factor Helios by Tregs ensures stable expression of a suppressive and anergic phenotype in the face of intense inflammatory responses, whereas Helios-deficient Tregs display diminished lineage stability, reduced FoxP3 expression, and production of proinflammatory cytokines. Here we report that selective Helios deficiency within CD4 Tregs leads to enhanced antitumor immunity through induction of an unstable phenotype and conversion of intratumoral Tregs into T effector cells within the tumor microenvironment. Induction of an unstable Treg phenotype is associated with enhanced production of proinflammatory cytokines by tumor-infiltrating but not systemic Tregs and significantly delayed tumor growth. Ab-dependent engagement of Treg surface receptors that result in Helios down-regulation also promotes conversion of intratumoral but not systemic Tregs into T effector cells and leads to enhanced antitumor immunity. These findings suggest that selective instability and conversion of intratumoral CD4 Tregs through genetic or Ab-based targeting of Helios may represent an effective approach to immunotherapy.
Expression of the transcription factor Helios by Tregs ensures stable expression of a suppressive and anergic phenotype in the face of intense inflammatory responses, whereas Helios-deficient Tregs display diminished lineage stability, reduced FoxP3 expression, and production of proinflammatory cytokines. Here we report that selective Helios deficiency within CD4 Tregs leads to enhanced antitumor immunity through induction of an unstable phenotype and conversion of intratumoral Tregs into T effector cells within the tumor microenvironment. Induction of an unstable Treg phenotype is associated with enhanced production of proinflammatory cytokines by tumor-infiltrating but not systemic Tregs and significantly delayed tumor growth. Ab-dependent engagement of Treg surface receptors that result in Helios down-regulation also promotes conversion of intratumoral but not systemic Tregs into T effector cells and leads to enhanced antitumor immunity. These findings suggest that selective instability and conversion of intratumoral CD4 Tregs through genetic or Ab-based targeting of Helios may represent an effective approach to immunotherapy. + Treg cells (nTregs), including recognition of tumor-associated antigens (TAAs) (1, 2) . These findings suggest that interventions that target Tregs may effectively complement current approaches aimed at checkpoints that control effector T-cell activation. Indeed, administration of Abs targeted at Tregs alone (e.g., TIGIT, CCR4, FR4) can strengthen antitumor immune responses (3) (4) (5) .
The transcription factor (TF) Helios is expressed by two regulatory T-cell lineages-FoxP3
+ and Ly49 + CD8 + Tregswhich are essential to maintain self-tolerance (6, 7) . Recent studies have revealed that Helios expression by Tregs ensures stable expression of a suppressive and anergic phenotype in the face of intense inflammatory responses, in part by ensuring Treg survival and stability through activation of the IL-2Rα-STAT5 pathway (6) . These observations have also suggested that loss of Treg lineage stability in inflammatory environments can result in conversion of Tregs into cells that express an effector T-cell phenotype and produce proinflammatory cytokines (6) .
The essential contribution of Helios to the maintenance of Treg size and functional stability in the face of diverse immunological perturbations may be relevant to the strategies that underpin current tumor immunotherapy. 
FoxP3
+ CD4 Tregs showed increased expression of KLRG1, GZMB, IL-10, and ICOS, i.e., molecules that are associated with robust suppressive activity ( Fig. 1 B and C) .FoxP3-Cre; Helios KO) mice after s.c. inoculation of transplantable melanoma (B16/F10) or colon adenocarcinoma (MC38). Helios KO mice showed substantial delay of tumor growth compared with Helios WT mice, resulting in prolonged survival ( Fig. 2 A and B) , indicating that Helios expression by FoxP3 + CD4 Tregs may normally contribute to Treg-mediated repression of antitumor immunity. Indeed, delayed tumor growth was associated with increased IFNγ production by CD8
+ TILs in Helios KO mice compared with TILs from Helios WT mice (Fig. 2C) .
Vaccination with GM-CSF-secreting irradiated tumor cells (GVAX) represents a prototypic paracrine cytokine adjuvant that induces differentiation of dendritic cells (DCs) leading to tumor antigen uptake, trafficking to tumor-draining lymph nodes, and enhanced inflammation. Because the contribution of the Helios TF to stable FoxP3 + Treg suppressive activity is critically important in inflammatory settings (6), we examined Helios WT and Helios KO mice after s.c. inoculation with B16-Ova melanoma cells and treatment with GVAX at days 3, 7, and 9. This regimen resulted in a substantial decrease in tumor growth in Helios KO mice compared with WT mice, indicating that Helios-deficient CD4 Tregs display reduced immunosuppressive activity (Fig. 2D) . Indeed, intratumoral CD4 and CD8 Teff cells in Helios KO mice expressed high levels of TNFα compared with modest levels by TILs from Helios WT mice (Fig. 2E ).
Enhanced Antitumor Immunity by Helios KO Mice Is Associated with an Unstable Treg Phenotype. Helios-deficient CD4 Tregs develop an unstable phenotype during inflammatory responses characterized by reduced FoxP3 expression and increased effector cytokine expression secondary to diminished activation of the STAT5 pathway (6) . Growing tumors attract a wide variety of cytokine/chemokine-producing leukocytes that shape the inflammatory microenvironment during tumor progression (10) and promote increased proportions of FoxP3 + CD4 cells compared with their frequency in lymphoid tissues. Thus, ∼40% of CD4 + cells within B16 melanoma are FoxP3 + , whereas ∼10% of splenic CD4 cells in tumor-bearing mice are FoxP3 + (Fig. 3A) . However, the frequency of FoxP3 + CD4 Tregs within CD4 + TILs in Helios KO mice is not increased (∼10-12%) compared with spleen (Fig. 3A) as judged from decreased ratio between FR4 hi CD73 hi (anergic) and FR4 lo CD73 lo (nonanergic) FoxP3 + cells (Fig. 3B) . This difference was confined to intratumoral CD4 Tregs; splenic FoxP3 + CD4 Tregs showed a similar anergic phenotype in tumor-bearing Helios WT and KO mice (Fig. 3B) . Consistent with their diminished anergic surface phenotype, Helios-deficient intratumoral CD4 Tregs expressed relatively high levels of the IFNγ effector cytokine, in contrast to WT intratumoral CD4 Tregs, which displayed a stable phenotype and minimal IFNγ production (Fig. 3C) . Conversion of Helios-deficient FoxP3 + CD4 Tregs to Teff cells was also noted in B16-bearing mice that had been treated with GVAX. Helios-deficient intratumoral Tregs expressed high levels of TNFα, whereas Helios WT intratumoral CD4 Tregs produced marginal levels (Fig. 3D) .
The Impact of Helios Deficiency in CD4 Tregs on Antitumor Immunity is Cell Intrinsic. To determine whether enhanced antitumor immunity displayed by Helios KO mice is Treg intrinsic, we transferred purified Helios WT or Helios KO CD4 Tregs (CD45.2) along with CD4 and CD8 Teff cells (CD45.1) into Rag2 −/− hosts and monitored for tumor growth. Rapid tumor growth was observed in hosts that had received WT CD4 Tregs, whereas tumor development was delayed in hosts that had received CD4 Tregs from Helios KO mice (Fig. 4A) (Fig. 4B) . FoxP3 down-regulation by Helios-deficient CD4 Tregs within tumors was more pronounced than in spleen, again suggesting that Helios expression by Tregs might be particularly important for stable FoxP3 expression within the chronic inflammatory environment of growing tumors. In accord with FoxP3 down-regulation, intratumoral Helios-deficient CD4 Tregs expressed high levels of IFNγ, suggesting a Treg→Teff cell conversion within the tumor (Fig. 4C) . Moreover, intratumoral CD4 and CD8 Teff cells in adoptive hosts transferred with Helios KO CD4 Tregs displayed increased IFNγ expression (Fig. 4D ).
Helios Deficiency Promotes in Vitro Conversion of Tregs into Teff
Cells. To further investigate the basis for the intrinsic instability of Helios-deficient CD4 Tregs, we used an in vitro system that allows analysis of Treg stability in the presence of inflammatory cytokines IL-2/IL-4 (6). Here we analyzed the responses of Helios +/+ and Helios −/− CD4 Tregs to graded concentrations of IL-2 and the proinflammatory cytokine IL-4 (11) (Fig. 5A) . Helios-deficient Tregs displayed profoundly reduced expression of both FoxP3 and CD25 and enhanced expression of IFNγ in an IL-2 dose-dependent manner (Fig. 5A) ; Helios WT CD4 Tregs expressed high levels of FoxP3 and CD25 that were not affected by IL-2 concentrations. Although Helios-deficient CD4 Tregs showed a significant increase in CD25 expression in the presence of higher concentrations of IL-2, it is unlikely that increased CD25 expression accounted for cytokine conversion, because FoxP3 lo cells marked by low CD25 expression produced the highest levels of IFNγ (Fig. 5B) . Taken together, these findings indicate that Helios makes a critical contribution to the stability and survival of FoxP3 + CD4 Tregs in the presence of inflammatory cytokines in this in vitro assay.
The dependence of CD4 Tregs on IL-2 for survival and lineage stability reflects, in part, an interaction between STAT5 and the FoxP3 intronic CNS2 region that promotes stable FoxP3 expression (12) . We previously noted that Helios may control STAT5-dependent stabilization of FoxP3 expression (6) . This hypothesis is strengthened by the finding that the unstable phenotype of Helios-deficient Tregs can be induced by blockade of STAT5 activation. The AG-490 STAT5 inhibitor reduced Treg survival, diminished FoxP3 expression, and enhanced IFNγ effector cytokine expression (Fig. 5C ). These data taken together suggest that approaches that down-regulate Helios in vivo may enhance tumor immunity via reduction of CD4 Treg numbers and conversion of a portion of the surviving Tregs into an effector cell phenotype.
Engagement of Glucocorticoid-Induced TNF Receptor Induces Helios Down-Regulation by CD4 Treg and Enhanced Antitumor Immunity.
The observation that Helios-deficient CD4 Treg convert to Teff cells within the TME and enhance antitumor responses opened the possibility that an immunotherapeutic regimen that induces Helios down-regulation might be exploited to enhance antitumor immunity. To this end, we used an in vitro Treg conversion assay (Fig. 5D ) to screen for Abs that induced conversion by Helios WT Tregs. One Ab identified was specific for glucocorticoidinduced TNF receptor (GITR), a member of the TNF receptor gene family that is prominently expressed by CD4 Tregs compared with other T cells that normally display low expression levels (13) . Engagement of GITR on CD4 Tregs by Abs in vitro in the presence of proinflammatory cytokine IL-4 resulted in induction of an unstable Treg phenotype characterized by reduced FoxP3 expression and IFNγ production (Fig. 5D) . Because the agonistic Ab DTA-1 has been shown to diminish CD4 Treg activity and enhance antitumor immunity, which has been attributed in part to decreased Treg lineage stability within tumors (14) , we tested whether engagement of GITR results in Helios down-regulation and enhanced antitumor immunity. Although repeated administration of a relatively low dose of DTA-1 (200 μg) did not induce obvious side effects (15) , both prophylactic and therapeutic regimens significantly delayed tumor growth (Fig.  6A ) and were associated with diminished expression of Helios and increased IFNγ production by intratumoral CD4 Tregs (Fig.  6B) . Moreover, CD8 Teff cells isolated from tumors in DTA-1-treated mice displayed increased IFNγ and TNFα production compared with CD8 Teff cells from isotype-control-treated mice (Fig. 6C) . The phenotypic changes in CD4 Tregs after DTA-1 (Fig. 6F) . However, the dramatic reduction in the anergic phenotype by DTA-1-treated CD4 Tregs indicates the impact of DTA-1 on the reactivity of Tregs is not limited to up-regulation of TNF-α/IFNγ. Together, these data suggest that the enhanced antitumor immunity after administration of DTA-1 reflects, at least in part, induction of an unstable CD4 Treg phenotype and Treg conversion. These data also suggest that Helios may represent a previously unrecognized target for cancer immunotherapy in light of its impact on intratumoral Treg stability.
Discussion
The definition of immunoinhibitory pathways that are up-regulated after T-cell activation has led to significant insight into tumor escape mechanisms. Many of these findings have been incorporated into approaches that combine checkpoint blockade with immunostimulatory agents that can promote sustained antitumor immune responses (16) . In some cases, these approaches also may affect Treg function. For example, the antitumor activity of some anti-CTLA-4 Abs may reflect FcγR-dependent depletion of intratumoral Tregs in addition to targeting of Teff cells (17) . Likewise, PD-1-based approaches may affect both Treg suppressive activity as well as effector T-cell responses (18) . Because depletion of Treg activity may also produce adverse autoimmune side effects (19) , approaches that preferentially target intratumoral Tregs without affecting the Treg systemic phenotype potentially represent a more effective strategy for cancer immunotherapy.
Here we show that a selective deficiency of Helios in FoxP3 Although the signaling pathway(s) that leads to effector cell conversion of Helios-deficient Tregs has not been identified, cytokine-mediated inflammation, competition for limited amounts of IL-2, and hypoxic conditions within the TME may promote conversion within the TME but not peripheral tissues, perhaps by skewing the pSTAT5/pSTAT3 ratio bound to Treg-specific demethylated regions (6, 12) . Because conversion of Helios-deficient Tregs occurs within the local inflammatory environment of the tumor (e.g., Figs. 3 and 4) , this approach may not provoke the autoimmune side effects associated with systemic reduction of Tregs (12, 16) . Although thymic-derived Tregs that recognize tissue-specific antigens expressed by tumors and their parent tissues may be highly represented within tumors (20) , under normal conditions, this autoreactive TCR repertoire does not translate into robust antitumor responses. Our data suggest that this tumor recognition bias of Treg may be exploited by approaches that induce Treg conversion into MHC class II/peptide-reactive effector cells that directly kill tumor cells (21) (22) (23) . These considerations suggest that protocols for transfer of TAA-specific CD4 T cells may benefit from approaches that down-regulate Helios expression by CD4 Tregs to obtain increased antitumor reactivity from both conventional CD4 cells and Helios-deficient converted Tregs.
This study also suggests that Treg→Teff conversion of Heliosdeficient Tregs within the local inflammatory setting of growing tumors can be mimicked by Ab-dependent engagement of surface receptors that down-regulate Helios expression. An in vitro screen of Abs that might reduce Helios expression and enhance Treg conversion suggested the potential contribution of GITR to this process. The impact of GITR Abs on tumor immunity has been described and may depend in part on engagement of GITR + Tregs (14) . We note that this TNFR costimulatory molecule, which is constitutively and highly expressed on Tregs and induced after activation of Teff cells, induces Helios down-regulation and Treg conversion that is restricted to tumor sites. Our CD4 Treg transfer experiments also suggest that potentiation of antitumor immunity by anti-GITR Ab administration can be attributed largely to induction of an unstable Treg phenotype.
Administration of anti-GITR Ab may lead to untoward side effects in mice (15); however, relatively low doses of anti-GITR Ab (200 μg) suffice to induce relatively selective Treg conversion, in view of the relatively low GITR levels expressed by activated Teff cells (13) . Although the mechanism that translates GITR ligation into an unstable nTreg phenotype is unknown, some recent studies may be relevant. Ligation of GITR inhibits induced-Treg (iTreg) generation and diverts these cells to the Th9 effector cell lineage, in part by inducing chromatin remodeling at the Foxp3 and Il9 loci via regulation of histone acetylation (24) . Induction of STAT6 after GITR ligation of iTregs also suggests that a similar GITR-dependent pathway in nTregs may enhance STAT6 competition with STAT5 for binding to CNS2, leading to diminished FoxP3 expression (12) . These findings suggest that administration of relatively low doses of anti-GITR Ab to impair Treg activity, perhaps in combination with T-cell-activating immunotherapy, may yield strong antitumor immunity. In sum, we anticipate that strategies that specifically harness Helios-dependent control of the intratumoral Treg phenotype hold significant promise for improving cancer immunotherapy.
Materials and Methods
Mice and Treatment. All mice were purchased from The Jackson Laboratory or Taconic Farms and maintained in specific pathogen-free conditions in the Dana-Farber Cancer Institute (DFCI) Animal Resource Facility. For tumor induction in B16/F10 and MC38 transplantable tumor models, mice were injected with 2 × Statistical Analysis. Statistical significance was calculated according to the Wilcoxon-Mann-Whitney rank sum test. A P value of <0.05 was considered to be statistically significant (*P < 0.05, **P < 0.01, ***P < 0.001).
